90Y-DOTATOC and nephrotoxicity.
Otte
Andreas
A
Cybulla
Markus
M
Weiner
Stefan M
SM
D000818:Animals; D002276:Carcinoid Tumor / Q000532:radiotherapy; D006801:Humans; D007414:Intestinal Neoplasms / Q000532:radiotherapy*; D007668:Kidney / Q000293:injuries / Q000528:radiation effects*; D007676:Kidney Failure, Chronic / Q000209:etiology; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use*
D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D015282:Octreotide; C106246:Edotreotide